Jeuveau™ (prabotulinumtoxinA-xvfs) – New drug approval
February 1, 2019 - Evolus announced the FDA approval of Jeuveau (prabotulinumtoxinA-xvfs), for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Top